Ribaxa+ 100mg Tablet

About Ribaxa+ 100mg Tablet

Ribaxa 100mg Tablet contains Olaparib, a targeted anticancer medication that belongs to the PARP (Poly ADP-ribose Polymerase) inhibitor class. It is used to treat certain types of prostate cancer and metastatic pancreatic cancer by blocking the PARP enzyme that cancer cells use to repair damaged DNA, thereby slowing cancer growth and promoting cancer cell death. Depending on the type and stage of cancer, Ribaxa 100mg Tablet may be prescribed alone or in combination with other anticancer therapies to improve treatment outcomes. Before starting treatment, patients should inform their healthcare provider about any history of liver, kidney, lung, or heart disease, as these conditions may require additional monitoring. Regular blood tests may be performed during therapy to monitor blood cell counts and assess treatment safety. Ribaxa 100mg Tablet is not recommended during pregnancy or breastfeeding because it may harm an unborn baby or nursing infant. Women of childbearing potential should undergo a pregnancy test before initiating treatment and use effective contraception during therapy as advised by their doctor. Male patients should avoid donating sperm during treatment and for at least three months after the final dose. Patients should also inform their doctor about all prescription medicines, over-the-counter medications, vitamins, herbal supplements, and dietary products they are taking to help prevent potential drug interactions and ensure the safe and effective use of Ribaxa 100mg Tablet.